drugset / Trial / NCT02844738

Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Shoulder

NCT02844738 ↗

Phase 2 Recruiting 4000 enrolled VivaTech International, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective open-label clinical study of 50 patients to determine safety and treatment potential of autologous cell therapy for pain and inflammation associated with Osteoarthritis of the shoulder. Follow-up will consist of a larger sample including 4,000 patients.

Timeline

Start
2015-07
Primary completion
2026-08
Completion
2026-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Platelet Rich Plasma Other / unclassified — Other
Subject StroMed Cell therapy — Other

Indications